Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For:	Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother 2000;1:507-14. [PMID: 11249534 DOI: 10.1517/14656566.1.3.507] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]

Number

Cited by Other Article(s)

Mohsen E, El Fishawy AM, Salama A, Elgohary R, Refaat A, Elgamal AM, Younis IY, Kamal RM. Unveiling the gastroprotective effect of the ethyl acetate fraction of Cordia africana Lam. roots against ethanol-induced gastric ulcer and Helicobacterpylori. JOURNAL OF ETHNOPHARMACOLOGY 2025;348:119841. [PMID: 40254109 DOI: 10.1016/j.jep.2025.119841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/03/2025] [Revised: 04/07/2025] [Accepted: 04/18/2025] [Indexed: 04/22/2025]

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Traditionally, Cordia africana Lam. roots, have been used in the treatment of gastro-intestinal complaints and the management of peptic ulcer diseases.

AIM OF THE STUDY

Quantitative determination of Cordia africana Lam. roots constituents was performed to investigate their phytochemical composition and their anti-ulcer mechanism.

MATERIALS AND METHODS

Cordia africana Lam. roots were subjected to extraction and fractionation. Antimicrobial activities of the extract and its factions were tested against Helicobacter pylori, and minimum inhibitory concentration (MIC) was measured. Then, an in vivo ethanol-induced model in rats was performed (at two tested doses: 200 mg/kg, 400 mg/kg, and pantoprazol 10 mg/kg against ethanol 5 mL/kg by oral gavage) with subsequent histopathological analysis. Oxidative and gastric inflammatory markers were measured. The phytochemical profile was confirmed using quantitative High-performance liquid chromatography (HPLC). Finally, molecular docking was performed to investigate the binding mode among the most abundant quantified compounds, viz., kaempferol, myricetin, naringenin, quercetin, and rosmarinic acid and three chosen proteins.

RESULTS

Among the tested fractions, Cordia africana ethyl acetate fraction (CAEt) gave the least MIC (7.82 μg/mL). Besides, at its high dose (400 mg/kg; orally), CAEt significantly reduced the ulcer number and severity by 26 % each, lowered malondialdehyde by 39 %, and increased glutathione and prostaglandin E2 levels by 92 % and 27 %, respectively, compared to pantoprazol. It exhibited similar potency to pantoprazol in decreasing tumor necrosis factor-alpha and cytokine-induced neutrophil chemoattractant-1, while it significantly decreased nuclear factor-kappa B more than pantoprazol by 7 %. Nineteen compounds were quantified using HPLC, showing that phenolic compounds and flavonoids were the most abundant phytoconstituents. In-silico molecular docking screening revealed the interaction between the five most quantified compounds and nuclear factor kappa B, prostaglandin E2, and tumor necrosis factor alpha proteins.

CONCLUSION

CAEt possesses potent gastroprotective properties via the reduction of gastric ulcer severity, decreasing oxidative stress, and inflammatory markers in ethanol-induced stomach damage. CAEt could be a promising candidate for gastric ulcer treatment and further studies on gastric-related diseases.

Collapse

Umar Z, Tang JW, Marshall BJ, Tay ACY, Wang L. Rapid diagnosis and precision treatment of Helicobacter pylori infection in clinical settings. Crit Rev Microbiol 2025;51:369-398. [PMID: 38910506 DOI: 10.1080/1040841x.2024.2364194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2024] [Revised: 05/08/2024] [Accepted: 05/25/2024] [Indexed: 06/25/2024]

Affiliation(s)

Zeeshan Umar Marshall Laboratory of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen, Guangdong Province, China Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China
Jia-Wei Tang Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China The Marshall Centre for Infectious Diseases Research and Training, The University of Western Australia, Crawley, Western Australia, China
Barry J Marshall Marshall Laboratory of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen, Guangdong Province, China The Marshall Centre for Infectious Diseases Research and Training, The University of Western Australia, Crawley, Western Australia, China Marshall International Digestive Diseases Hospital, Zhengzhou University, Zhengzhou, Henan Province, China Marshall Medical Research Center, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Alfred Chin Yen Tay Marshall Laboratory of Biomedical Engineering, School of Medicine, Shenzhen University, Shenzhen, Guangdong Province, China The Marshall Centre for Infectious Diseases Research and Training, The University of Western Australia, Crawley, Western Australia, China Marshall International Digestive Diseases Hospital, Zhengzhou University, Zhengzhou, Henan Province, China Marshall Medical Research Center, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Liang Wang Laboratory Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong Province, China Division of Microbiology and Immunology, School of Biomedical Sciences, The University of Western Australia, Crawley, Western Australia, China Center for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, China School of Agriculture and Food Sustainability, University of Queensland, Brisbane, Queensland, Australia

Collapse

Du Y, Semghouli A, Wang Q, Mei H, Kiss L, Baecker D, Soloshonok VA, Han J. FDA-approved drugs featuring macrocycles or medium-sized rings. Arch Pharm (Weinheim) 2025;358:e2400890. [PMID: 39865335 PMCID: PMC11771699 DOI: 10.1002/ardp.202400890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Revised: 12/20/2024] [Accepted: 12/22/2024] [Indexed: 01/28/2025]

Ovchinnikov DV, Vakhrameev SA, Voronov IS, Semushina MP, Ul'yanovskii NV, Kosyakov DS. Determination of Macrolides in Water Using Solid-Phase Extraction and Supercritical Fluid Chromatography-Tandem Mass Spectrometry. J Sep Sci 2024;47:e70000. [PMID: 39460572 DOI: 10.1002/jssc.70000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Revised: 09/30/2024] [Accepted: 10/06/2024] [Indexed: 10/28/2024]

Mozaffari S, Mousavi T, Nikfar S, Abdollahi M. Common gastrointestinal drug-drug interactions in geriatrics and the importance of careful planning. Expert Opin Drug Metab Toxicol 2023;19:807-828. [PMID: 37862038 DOI: 10.1080/17425255.2023.2273384] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 10/17/2023] [Indexed: 10/21/2023]

Venditto VJ, Feola DJ. Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions. Adv Drug Deliv Rev 2022;184:114252. [PMID: 35367307 PMCID: PMC9063468 DOI: 10.1016/j.addr.2022.114252] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 03/07/2022] [Accepted: 03/28/2022] [Indexed: 12/17/2022]

Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 PMCID: PMC8275651 DOI: 10.3389/pore.2021.1609863] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 06/16/2021] [Indexed: 01/06/2023]

Abstract

The global rise in clarithromycin (Cla) resistance is considered to be the main contributor of Helicobacter pylori (Hp) eradication failures. In nearly half of the Cla-resistant Hp infections, Cla-susceptible bacteria are simultaneously present with the Cla-resistant ones (Cla-heteroresistance). The proportion of resistant bacteria in the bacterial population (R-fraction) and its predictive role for the use of Cla-based therapies in Cla-heteroresistant infections has not yet been investigated. Our retrospective study analyzed gastric biopsy samples of 62 Hp-positive patients with Cla-heteroresistant infection. Fluorescence In Situ Hybridization technique was used to visualize the coexistence of resistant and susceptible bacteria within one tissue sample. R-fraction was quantified on multichannel microimages by digital morphometry. Resistant bacteria had a patchy distribution within the whole bacterial population causing high diversity among the investigated areas. Patients were subdivided into two major groups according to whether a Cla-based eradication attempt was conducted before or after the biopsy sampling. R-fraction was significantly lower among cases having only one previous Cla-based eradication attempt vs. those that had multiple previous eradications, including at least one Cla-containing therapy (0.41 vs. 0.89, p = 0.0308). Majority of the patients without previous eradication attempt had successful eradication with Cla-containing regimen (59.26%), verified by a negative ¹³C-urea breath test or control biopsy. Multivariable model indicated that the therapeutic outcome using Cla-based regimens depended on the bacterial density rather than the R-fraction. Our study raises the potential use of Cla-containing eradication therapies in certain Cla-heteroresistant Hp infections, taking into account the possible predictive role of bacterial density.

Collapse

Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 PMCID: PMC7924850 DOI: 10.3390/antibiotics10020214] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2021] [Revised: 02/14/2021] [Accepted: 02/18/2021] [Indexed: 12/12/2022] Open

Affiliation(s)

Seokin Kang Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Yuri Kim Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Ji Yong Ahn Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Hwoon-Yong Jung Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Nayoung Kim Asan Medical Center, Department of Clinical Epidemiology and Biostatistics, University of Ulsan College of Medicine, Seoul 05505, Korea;
Hee Kyong Na Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Jeong Hoon Lee Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Kee Wook Jung Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Do Hoon Kim Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Kee Don Choi Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Ho June Song Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)
Gin Hyug Lee Asan Medical Center, Department of Gastroenterology, University of Ulsan College of Medicine, Seoul 05505, Korea; (S.K.); (Y.K.); (H.K.N.); (J.H.L.); (K.W.J.); (D.H.K.); (K.D.C.); (H.J.S.); (G.H.L.)

Collapse

Salehi N, Attaran B, Zare-Mirakabad F, Ghadiri B, Esmaeili M, Shakaram M, Tashakoripour M, Eshagh Hosseini M, Mohammadi M. The outward shift of clarithromycin binding to the ribosome in mutant Helicobacter pylori strains. Helicobacter 2020;25:e12731. [PMID: 32794288 DOI: 10.1111/hel.12731] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2020] [Revised: 06/30/2020] [Accepted: 07/03/2020] [Indexed: 02/06/2023]

Yen CH, Chiu HF, Huang SY, Lu YY, Han YC, Shen YC, Venkatakrishnan K, Wang CK. Beneficial effect of Burdock complex on asymptomatic Helicobacter pylori-infected subjects: A randomized, double-blind placebo-controlled clinical trial. Helicobacter 2018;23:e12469. [PMID: 29520881 DOI: 10.1111/hel.12469] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]

Rajput P, Singh D, Pathak K. Bifunctional capsular dosage form: Novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. Int J Pharm 2014;461:310-21. [DOI: 10.1016/j.ijpharm.2013.11.053] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2013] [Revised: 11/21/2013] [Accepted: 11/23/2013] [Indexed: 11/26/2022]

Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, Tse F, Calvet X, Fallone C, Fischbach L, Oderda G, Bazzoli F, Moayyedi P, Cochrane Upper GI and Pancreatic Diseases Group. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;2013:CD008337. [PMID: 24338763 PMCID: PMC11841770 DOI: 10.1002/14651858.cd008337.pub2] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]

Abstract

BACKGROUND

The optimal duration for Helicobacter pylori (H. pylori) eradication therapy is controversial, with recommendations ranging from 7 to 14 days. Several systematic reviews have attempted to address this issue but have given conflicting results and limited their analysis to proton pump inhibitor (PPI), two antibiotics (PPI triple) therapy. We performed a systematic review and meta-analysis to investigate the optimal duration of multiple H. pylori eradication regimens.

OBJECTIVES

The primary objective was to assess the relative effectiveness of different durations (7, 10 or 14 days) of a variety of regimens for eradicating H. pylori. The primary outcome was H. pylori persistence. The secondary outcome was adverse events.

SEARCH METHODS

The Cochrane Library, MEDLINE, EMBASE, and CINAHL were searched up to December 2011 to identify eligible randomised controlled trials (RCTs). We also searched the proceedings of six conferences from 1995 to 2011, dissertations and theses, and grey literature. There were no language restrictions applied to any search.

SELECTION CRITERIA

Only parallel group RCTs assessing the efficacy of one to two weeks duration of first line H. pylori eradication regimens in adults were eligible. Within each regimen, the same combinations of drugs at the same dose were compared over different durations. Studies with at least two arms comparing 7, 10, or 14 days were eligible. Enrolled participants needed to be diagnosed with at least one positive test for H. pylori on the basis of a rapid urease test (RUT), histology, culture, urea breath test (UBT), or a stool antigen test (HpSA) before treatment. Eligible trials needed to confirm eradication of H. pylori as their primary outcome at least 28 days after completion of eradication treatment. Trials using only serology or a polymerase chain reaction (PCR) to determine H. pylori infection or eradication were excluded.

DATA COLLECTION AND ANALYSIS

Study eligibility and data extraction were performed by two independent review authors. Data analyses were performed within each type of intervention, for both primary and secondary outcomes. The relative risk (RR) and number needed to treat (NNT)/number needed to harm (NNTH) according to duration of therapy were calculated using the outcomes of H. pylori persistence and adverse events. A random-effects model was used. Subgroup analyses and sensitivity analyses were planned a priori.

MAIN RESULTS

In total, 75 studies met the inclusion criteria. Eight types of regimens were reported with at least two comparative eligible durations. They included: PPI + two antibiotics triple therapy (n = 59), PPI bismuth-based quadruple therapy (n = 6), PPI + three antibiotics quadruple therapy (n = 1), PPI dual therapy (n = 2), histamine H2-receptor antagonist (H₂RA) bismuth quadruple therapy (n = 3), H₂RA bismuth-based triple therapy (n = 2), H₂RA + two antibiotics triple therapy (n = 3), and bismuth + two antibiotics triple therapy (n = 2). Some studies provided data for more than one regimen or more than two durations.For the PPI triple therapy, 59 studies with five regimens were reported: PPI + clarithromycin + amoxicillin (PCA); PPI + clarithromycin + a nitroimidazole (PCN); PPI + amoxicillin + nitroimidazole (PAN); PPI + amoxicillin + a quinolone (PAQ); and PPI + amoxicillin + a nitrofuran (PANi). Regardless of type and dose of antibiotics, increased duration of PPI triple therapy from 7 to 14 days significantly increased the H. pylori eradication rate (45 studies, 72.9% versus 81.9%), the RR for H. pylori persistence was 0.66 (95% CI 0.60 to 0.74), NNT was 11 (95% CI 9 to 14). Significant effects were seen in the subgroup of PCA (34 studies, RR 0.65, 95% CI 0.57 to 0.75; NNT 12, 95% CI 9 to 16); PAN (10 studies, RR 0.67, 95% CI 0.52 to 0.86; NNT = 11, 95% CI 8 to 25); and in PAQ (2 studies, RR 0.37, 95% CI 0.16 to 0.83; NNT 3, 95% CI 2 to 10); but not in PCN triple therapy (4 studies, RR 0.87, 95% CI 0.71 to 1.07). Significantly increased eradication rates were also seen for PPI triple therapy with 10 versus 7 days (24 studies, 79.9% versus 75.7%; RR 0.80, 95% CI 0.72 to 0.89; NNT 21, 95% CI 15 to 38) and 14 versus 10 days (12 studies, 84.4% versus 78.5%; RR 0.72, 95% CI 0.58 to 0.90; NNT 17, 95% CI 11 to 46); especially in the subgroup of PAC for 10 versus 7 days (17 studies, RR 0.80, 95% CI 0.70 to 0.91) and for 14 versus 10 days (10 studies, RR 0.69, 95% CI 0.52 to 0.91). A trend towards increased H. pylori eradication rates was seen with increased duration of PCN for 10 versus 7 days, and of PAN for 10 versus 7 days and 14 versus 10 days, though this was not statistical significant. The proportion of patients with adverse events, defined by authors, was marginally significantly increased only between 7 days and 14 days (15.5% versus 19.4%; RR 1.21, 95% CI 1.06 to 1.37; NNTH 31, 95% CI 18 to 104) but not for other duration comparisons. The proportion of patients discontinuing treatment due to adverse events was not significantly different between treatment durations.Only limited data were reported for different durations of regimens other than PPI triple therapy. No significant difference of the eradication rate was seen for all regimens according to different durations except for H₂RA bismuth quadruple therapy, where a significantly higher eradication rate was seen for 14 days versus 7 days, however only one study reported outcome data.

AUTHORS' CONCLUSIONS

Increasing the duration of PPI-based triple therapy increases H. pylori eradication rates. For PCA, prolonging treatment duration from 7 to 10 or from 10 to 14 days is associated with a significantly higher eradication rate. The optimal duration of therapy for PCA and PAN is at least 14 days. More data are needed to confirm if there is any benefit of increasing the duration of therapy for PCN therapy. Information is limited for regimens other than PPI triple therapy; more studies are needed to draw meaningful conclusions for optimal duration of other H. pylori eradication regimens.

Collapse

Affiliation(s)

Yuhong Yuan McMaster UniversityDepartment of Medicine, Division of Gastroenterology1280 Main Street WestHamiltonOntarioCanadaL8S 4K1
Alex C Ford St. James's University HospitalDepartment of Academic MedicineBeckett StreetLeedsUKLS9 7TF
Khurram J Khan McMaster UniversityDepartment of Medicine, Division of Gastroenterology1280 Main Street WestHamiltonOntarioCanadaL8S 4K1
Javier P Gisbert Gastroenterology Unit, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)MadridSpain
David Forman International Agency for Research on Cancer150 cours Albert‐ThomasLyonFrance69372
Grigorios I Leontiadis McMaster UniversityDepartment of Medicine, Division of Gastroenterology1280 Main Street WestHamiltonOntarioCanadaL8S 4K1
Frances Tse McMaster UniversityDepartment of Medicine, Division of Gastroenterology1280 Main Street WestHamiltonOntarioCanadaL8S 4K1
Xavier Calvet Hospital de Sabadell & Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd)Servei de Malalties DigestivesParc Taulí, s/nSabadellSpain08208
Carlo Fallone McGill University Health CentreFaculty of MedicineRoyal Victoria Hospital687 Pine Avenue West, Room R228MontrealQuebecCanadaH3A 1A1
Lori Fischbach University of Arkansas for Medical SciencesDepartment of Epidemiology4301 West Markham, # 820Little RockARUSA
Giuseppina Oderda Universita del Piemonte OrientalePaediatric Endoscopy UnitsVia Solaroli 17NovaraItaly28100
Franco Bazzoli Università degli Studi di BolognaDipartimento di Scienze Mediche e ChirurgichePoliclinico S.OrsolaVia Massarenti 9, Via Borgo San Pietro 137BolognaItalyI‐40138
Paul Moayyedi McMaster UniversityDepartment of Medicine, Division of Gastroenterology1280 Main Street WestHamiltonOntarioCanadaL8S 4K1
Cochrane Upper GI and Pancreatic Diseases Group

Collapse

Morimura T, Hashiba M, Kameda H, Takami M, Takahama H, Ohshige M, Sugawara F. Identification of Macrolide Antibiotic-binding Human_p8 Protein. J Antibiot (Tokyo) 2008;61:291-6. [DOI: 10.1038/ja.2008.41] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. Inhibition of Helicobacter pylori in vitro by various berry extracts, with enhanced susceptibility to clarithromycin. Mol Cell Biochem 2005;265:19-26. [PMID: 15543930 DOI: 10.1023/b:mcbi.0000044310.92444.ec] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]

Zavros Y, Merchant JL. Modulating the cytokine response to treat Helicobacter gastritis. Biochem Pharmacol 2005;69:365-71. [PMID: 15652228 DOI: 10.1016/j.bcp.2004.07.043] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2004] [Accepted: 07/30/2004] [Indexed: 01/20/2023]

Chatterjee A, Bagchi D, Yasmin T, Stohs SJ. Antimicrobial effects of antioxidants with and without clarithromycin on Helicobacter pylori. Mol Cell Biochem 2005;270:125-30. [PMID: 15792361 DOI: 10.1007/s11010-005-5277-0] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]

Abstract

Increasing resistance to currently used antimicrobials has resulted in the evaluation of other agents that have antimicrobial activity against Helicobacter pylori. H. pylori American Type Culture Collection (ATCC) strain 49503 (a toxin-producing strain known to be associated with gastric cancer) was grown, a cell suspension prepared in 2 mL PBS and diluted 10-fold. One hundred microL of this cell suspension was added to vitamin C 0.5%, vitamin E 0.5%, garcinol 100 microg/mL, Protykin (containing 50% trans-resveratrol) 100 microg/mL and garcinol + Protykin 100 microg/mL in Lennox broth, and incubated for 16 h under microaerophilic conditions. Three replicates of 10 microL from each 10(-7) dilution tube were plated, colonies were counted after 16 h, and growth of H. pylori was confirmed by the CLO test. These colony counts were compared to control cultures without the addition of any antioxidants. The experiments were then repeated with the addition of 15 microg/mL of clarithromycin to experimental and control samples. Enhanced killing of H. pylori by 37.6% was noted when vitamin C was added, which increased to 66% when clarithromycin was added, compared to controls (p < 0.05). With garcinol and Protykin alone there was 91.4 and 87% killing of H. pylori, respectively, while a combination of garcinol + Protykin resulted in 90.8% killing compared to controls (p < 0.05). When clarithromycin was added, there was 76.3% increased killing with garcinol alone, 55.3% with Protykin alone, and 73.7% with garcinol + Protykin compared to controls (containing clarithromycin) (p < 0.05). Vitamin E had no effect on H. pylori growth compared to controls. We conclude from this study that some antioxidants such as vitamin C, garcinol and Protykin, but not vitamin E, may have potential as antimicrobial agents against H. pylori.

Collapse

Chatterjee A, Yasmin T, Bagchi D, Stohs SJ. The bactericidal effects of Lactobacillus acidophilus, garcinol and Protykin compared to clarithromycin, on Helicobacter pylori. Mol Cell Biochem 2003;243:29-35. [PMID: 12619886 DOI: 10.1023/a:1021649427988] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]

Leung WK, Hung LCT, Kwok CKL, Leong RWL, Ng DKK, Sung JJY. Follow up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections. World J Gastroenterol 2002;8:703-6. [PMID: 12174382 PMCID: PMC4656324 DOI: 10.3748/wjg.v8.i4.703] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open

Malhotra S, Pandhi P. Eradication of Helicobacter pylori: current perspectives. Expert Opin Pharmacother 2002;3:1031-8. [PMID: 12150683 DOI: 10.1517/14656566.3.8.1031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]

Leung WK, Graham DY. Rescue Therapy for Helicobacter pylori. CURRENT TREATMENT OPTIONS IN GASTROENTEROLOGY 2002;5:133-138. [PMID: 11879593 DOI: 10.1007/s11938-002-0060-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]

Gomollón F, Sicilia B. Helicobacter pylori: strategies for treatment. Expert Opin Investig Drugs 2001;10:1231-41. [PMID: 11772247 DOI: 10.1517/13543784.10.7.1231] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]